 Because acute promyelocytic leukemia ( APL ) has the highest curability and requires a unique form of treatment , it is important to quickly establish or exclude the diagnosis of this subtype of leukemia . Fluorescent in situ hybridization performed on blood or bone marrow is often used for this purpose , as it readily identifies the chromosomal translocation [ t ( 15 ; 17 ) ( q22 ; q12 ) ; ] that characterizes APL . There is also a need to molecularly detect the presence of PML / RARA fusion protein , which is an oncogenic product of that translocation . 
 Because acute promyelocytic leukemia ( APL ) <a href='got' title='1'><mark>has</mark></a> the highest curability and <a href='uninflect' title='2'><mark>requires</mark></a> a unique form of treatment , it <a href='drop_aux' title='3'><mark>is</mark></a>important to quickly establish or exclude the diagnosis of this subtype of leukemia . Fluorescent in situ hybridization performed on blood or bone marrow is often used for this purpose , as it readily <a href='uninflect' title='4'><mark>identifies</mark></a> the chromosomal translocation [ t ( 15 ; 17 ) ( q22 ; q12 ) ; ] <a href='null_relcl' title='5'><mark>that</mark></a><a href='uninflect' title='6'><mark>characterizes</mark></a> APL . <a href='dey_it' title='7'><mark>There</mark></a> is also a need to molecularly detect the presence of PML / RARA fusion protein , which <a href='drop_aux' title='8'><mark>is</mark></a>an oncogenic product of that translocation . 
Because acute promyelocytic leukemia ( APL ) got da highest curability and require a unique form of treatment , it important to quickly establish or exclude the diagnosis of dis subtype of leukemia . Fluorescent in situ hybridization performed on blood or bone marrow is often used fir tdispurpose , as it readily identify tdachromosomal translocation [ t ( 15 ; 17 ) ( q22 ; q12 ) ; ] characterize APL . It is also a gotta molecularly detect the presence of PML / RARA fusion protein , which an oncogenic product of that translocation .